MA28928B1 - Indazoles, benzisoxazoles et benzisothiazoles et leur utilisation en tant qu'agents oestrogeniques - Google Patents

Indazoles, benzisoxazoles et benzisothiazoles et leur utilisation en tant qu'agents oestrogeniques

Info

Publication number
MA28928B1
MA28928B1 MA29816A MA29816A MA28928B1 MA 28928 B1 MA28928 B1 MA 28928B1 MA 29816 A MA29816 A MA 29816A MA 29816 A MA29816 A MA 29816A MA 28928 B1 MA28928 B1 MA 28928B1
Authority
MA
Morocco
Prior art keywords
benzisoxazoles
benzisothiazoles
indazoles
estrogenic agents
estrogenic
Prior art date
Application number
MA29816A
Other languages
English (en)
Inventor
Benoit Rondot
Jean Lafay
Paule Bonnet
Thierry Clerc
Igor Duc
Eric Duranti
Francois Puccio
Jacqueline Shields
Christian Blot
Philippe Maillos
Original Assignee
Theramex
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theramex filed Critical Theramex
Publication of MA28928B1 publication Critical patent/MA28928B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA29816A 2004-10-14 2007-04-09 Indazoles, benzisoxazoles et benzisothiazoles et leur utilisation en tant qu'agents oestrogeniques MA28928B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04292439A EP1647549A1 (fr) 2004-10-14 2004-10-14 Indazoles, benzisoxazoles et benzisothiazoles en tant qu'agents oestrogéniques

Publications (1)

Publication Number Publication Date
MA28928B1 true MA28928B1 (fr) 2007-10-01

Family

ID=34931452

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29816A MA28928B1 (fr) 2004-10-14 2007-04-09 Indazoles, benzisoxazoles et benzisothiazoles et leur utilisation en tant qu'agents oestrogeniques

Country Status (24)

Country Link
US (2) US7977364B2 (fr)
EP (2) EP1647549A1 (fr)
JP (1) JP5047801B2 (fr)
KR (1) KR20070109976A (fr)
CN (1) CN101080395B (fr)
AP (1) AP2007003960A0 (fr)
AR (1) AR051457A1 (fr)
AT (1) ATE512952T1 (fr)
AU (1) AU2005293509B2 (fr)
BR (1) BRPI0516851A (fr)
CA (1) CA2582180C (fr)
ES (1) ES2368203T3 (fr)
IL (1) IL182047A (fr)
MA (1) MA28928B1 (fr)
MX (1) MX2007004372A (fr)
NO (1) NO20071922L (fr)
NZ (1) NZ554279A (fr)
RU (1) RU2402536C2 (fr)
SG (1) SG158886A1 (fr)
TN (1) TNSN07138A1 (fr)
TW (1) TW200619202A (fr)
UA (1) UA90280C2 (fr)
WO (1) WO2006040351A1 (fr)
ZA (1) ZA200702690B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1647549A1 (fr) * 2004-10-14 2006-04-19 Laboratoire Theramex Indazoles, benzisoxazoles et benzisothiazoles en tant qu'agents oestrogéniques
JP4965270B2 (ja) * 2007-01-16 2012-07-04 出光興産株式会社 アダマンチルカルボニル基含有芳香族ジオール、その誘導体及びそれらの製造方法
FR2913019A1 (fr) * 2007-02-23 2008-08-29 Cerep Sa Composes heterocycliques comme agents anti-neoplasiques ou inhibiteurs de proliferation cellulaire
GB0704407D0 (en) 2007-03-07 2007-04-18 Glaxo Group Ltd Compounds
GB0803017D0 (en) 2008-02-19 2008-03-26 Glaxo Group Ltd Compounds
EP2710007B1 (fr) * 2011-05-17 2019-12-11 The Regents of The University of California Inhibiteurs de kinase
US20150018398A1 (en) * 2013-07-15 2015-01-15 The Regents Of The University Of California Methods of using estrogen receptor-beta ligands as radiation mitigators
DE102015012050A1 (de) * 2015-09-15 2017-03-16 Merck Patent Gmbh Verbindungen als ASIC-Inhibitoren und deren Verwendungen
CN109111407A (zh) * 2017-06-23 2019-01-01 江苏恩华药业股份有限公司 一种苯并异恶唑类化合物衍生物及其应用
US10392368B2 (en) 2017-08-01 2019-08-27 Theravance Biopharma R&D Ip, Llc Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors
CN110117278B (zh) * 2018-02-07 2022-07-19 石家庄以岭药业股份有限公司 烷氧基苯并五元(六元)杂环胺类化合物及其药物用途
WO2020154350A1 (fr) 2019-01-23 2020-07-30 Theravance Biopharma R&D Ip, Llc Imidazo[1,5-a]pyridine,1,2,4-triazolo[4,3-a]pyridine et imidazo[1,5-a]pyrazine utilisées en tant qu'inhibiteurs de jak

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1406882A (en) 1972-04-28 1975-09-17 Leo Pharm Prod Ltd Benzoic acid derivatives and benzisptjoaup'e 1.1 dopxode derovatoves
JPS50157363A (fr) * 1974-06-06 1975-12-19
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
ATE236137T1 (de) * 1996-02-02 2003-04-15 Merck & Co Inc Heterocyclische verbindungen als antidiabetische mittel und für die behandlung von fettleibigkeit
US6090836A (en) * 1996-02-02 2000-07-18 Merck & Co., Inc. Benzisoxazole-derived antidiabetic compounds
US6008237A (en) * 1997-12-19 1999-12-28 Merck & Co., Inc. Arylthiazolidinedione derivatives
EP1194146B1 (fr) * 1999-06-18 2006-07-19 Merck & Co., Inc. Derives d'arylthiazolidinedione et d'aryloxazolidinedione
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
GB0002666D0 (en) * 2000-02-04 2000-03-29 Univ London Blockade of voltage dependent sodium channels
JP2001288175A (ja) * 2000-04-06 2001-10-16 Nippon Soda Co Ltd ヒドロキシベンゾイソオキサゾール化合物、製造方法、製造中間体、抗真菌薬および農園芸用殺菌剤
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
DE10046029A1 (de) * 2000-09-18 2002-03-28 Bayer Ag Indazole
EP1334094B1 (fr) * 2000-11-02 2004-12-29 F. Hoffmann-La Roche Ag Benzo[b]thiophenes et benzo[d]isothiazoles hypocholesterolemiants
US6608409B2 (en) * 2001-05-15 2003-08-19 General Electric Company High temperature super-conducting rotor having a vacuum vessel and electromagnetic shield and an assembly method
EP1392658A4 (fr) * 2001-06-01 2004-10-13 Alcon Inc Indazoles et indoles nouveaux fusionnes et leur utilisation dans le traitement de glaucomes
EP1403255A4 (fr) 2001-06-12 2005-04-06 Sumitomo Pharma Inhibiteurs de rho kinase
JP4542338B2 (ja) * 2001-09-26 2010-09-15 ファイザー イタリア ソシエタ ア レスポンサビリタ リミタータ キナーゼ阻害因子として活性なアミノインダゾール誘導体、それらの製造方法及びそれらを含有する医薬組成物
US6884814B2 (en) * 2001-12-13 2005-04-26 Wyeth Phenyl benzisoxazoles as estrogenic agents
US6960607B2 (en) * 2001-12-13 2005-11-01 Wyeth Naphthyl benzoxazoles and benzisoxazoles as estrogenic agents
US7104676B2 (en) * 2002-04-15 2006-09-12 K.W. Muth Company, Inc. Signaling assembly
WO2003101968A1 (fr) * 2002-05-31 2003-12-11 Eisai Co., Ltd. Compose de pyrazole et composition medicinale le contenant
TW200400177A (en) * 2002-06-04 2004-01-01 Wyeth Corp 1-(Aminoalkyl)-3-sulfonylindole and-indazole derivatives as 5-hydroxytryptamine-6 ligands
TW200401641A (en) * 2002-07-18 2004-02-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands
KR101166745B1 (ko) 2002-09-05 2012-07-23 아방티 파르마 소시에테 아노님 의약으로서의 신규한 아미노인다졸 유도체 및 이를 함유하는 약제학적 조성물
TW200409759A (en) * 2002-09-25 2004-06-16 Wyeth Corp Substituted 4-(indazol-3-yl)phenols
US7196082B2 (en) 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
JP2006510742A (ja) 2002-11-08 2006-03-30 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧治療用眼科組成物
PL376789A1 (pl) 2002-12-12 2006-01-09 Aventis Pharma S.A. Pochodne aminoindazoli i ich zastosowanie jako inhibitorów kinazy
US7521447B2 (en) * 2003-03-03 2009-04-21 Array Biopharma Inc. P38 inhibitors and methods of use thereof
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7592494B2 (en) * 2003-07-25 2009-09-22 Honeywell International Inc. Process for the manufacture of 1,3,3,3-tetrafluoropropene
DE10339719A1 (de) * 2003-08-28 2005-03-24 BSH Bosch und Siemens Hausgeräte GmbH Blähkörper zum Trocknen und/oder Glätten von Kleidungsstücken
FR2864084B1 (fr) 2003-12-17 2006-02-10 Aventis Pharma Sa Nouveaux derives organophosphores des indazoles et leur utilisation comme medicaments
KR20060114022A (ko) * 2004-02-27 2006-11-03 에프. 호프만-라 로슈 아게 인다졸 유도체 및 그들을 함유하는 약학 조성물
WO2006010595A1 (fr) * 2004-07-27 2006-02-02 Novartis Ag Inhibiteurs de hsp90
EP1647549A1 (fr) * 2004-10-14 2006-04-19 Laboratoire Theramex Indazoles, benzisoxazoles et benzisothiazoles en tant qu'agents oestrogéniques

Also Published As

Publication number Publication date
MX2007004372A (es) 2007-06-07
ES2368203T3 (es) 2011-11-15
AU2005293509A1 (en) 2006-04-20
ZA200702690B (en) 2008-10-29
WO2006040351A1 (fr) 2006-04-20
UA90280C2 (ru) 2010-04-26
AP2007003960A0 (en) 2007-04-30
US20110237624A1 (en) 2011-09-29
CN101080395B (zh) 2011-08-17
ATE512952T1 (de) 2011-07-15
EP1812404B1 (fr) 2011-06-15
SG158886A1 (en) 2010-02-26
NZ554279A (en) 2010-09-30
JP2008516929A (ja) 2008-05-22
JP5047801B2 (ja) 2012-10-10
AR051457A1 (es) 2007-01-17
IL182047A0 (en) 2007-07-24
US20090023779A1 (en) 2009-01-22
IL182047A (en) 2013-03-24
US7977364B2 (en) 2011-07-12
BRPI0516851A (pt) 2008-09-23
EP1647549A1 (fr) 2006-04-19
US8173679B2 (en) 2012-05-08
EP1812404A1 (fr) 2007-08-01
CA2582180A1 (fr) 2006-04-20
TW200619202A (en) 2006-06-16
KR20070109976A (ko) 2007-11-15
RU2007117714A (ru) 2008-11-20
CA2582180C (fr) 2013-04-30
NO20071922L (no) 2007-07-06
RU2402536C2 (ru) 2010-10-27
AU2005293509B2 (en) 2012-01-12
CN101080395A (zh) 2007-11-28
TNSN07138A1 (en) 2008-11-21

Similar Documents

Publication Publication Date Title
MA28928B1 (fr) Indazoles, benzisoxazoles et benzisothiazoles et leur utilisation en tant qu'agents oestrogeniques
EP1755591A4 (fr) Formulations ophtalmiques comprenant des antagonistes selectifs des recepteurs alpha 1
MXPA05012249A (es) Derivados de arilcarbaldehido oxima y su uso como agentes estrogenicos.
DE502004004205D1 (de) Gegen missbrauch gesicherte darreichungsform
ATE389327T1 (de) Herbizid wirksames mittel
DE602004015286D1 (de) Wäschebehandlungsmittel
ATE453391T1 (de) Östrogene mittel enthaltende arzneizusammensetzungen
ATE354631T1 (de) Nuancierungsmittel
ATE516030T1 (de) Benzimidazolidinon-derivate als muscarinische mittel
NL1026490A1 (nl) Instructiesetextensie onder gebruikmaking van 3-byte escape opcode.
DE602004008230D1 (de) Abgabe- und mischspitze
DE502004005842D1 (de) Flüssige formulierung
MA28602B1 (fr) Pyridin-4-yl-ethynyl-imidazoles et pyrazoles en tant qu'antagonistes des recepteurs mglur5
ITTO20021031A1 (it) Dispositivo per l'erogazione di almeno un agente di
ATE460415T1 (de) Therapeutische pyrazoloä3,4-büpyridine und - indazole
FR2879459B1 (fr) Composition comprenant de l'adapalene solubilise avec des cyclodextrines
ATE337322T1 (de) Isoxazolin-derivate als antidepressiva
DE60114039D1 (de) Kautschukzusammensetzungen und vulkanisate einschliesslich verzweigter kammpolymere
GB0326221D0 (en) Therapeutic agents,compositions,preparations and uses
FR2859910B1 (fr) Utilisation du 1-alpha-fluoro-25-hydroxy-16,23e-diene-26,27- bishomo-20-epi-cholecalciferol pour le traitement de l'hyperplasie benigne de la prostate
SE0301890L (sv) Handmixer
DE60333581D1 (de) Bewuchsverhinderndes dispersionsmittel
PT1305314E (pt) Agente terapeutico cristalino
ITMI20051135A1 (it) "dispositivo dosatore"
DE112004001429D2 (de) Pharmazeutischer Wirkstoff